Enasidenib/azacitidine was evaluated for high-risk IDH2-mutated MDS, demonstrating a response rate of 74% and a complete remission of 26% in 27% of patients proceeding to alloBMT and survival after 2 years [182]. Here, IDH2 is linked to myelodysplastic syndrome.